Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

PPHMD

Peregrine Pharmaceuticals Inc. (MM) (PPHMD)

Peregrine Pharmaceuticals Inc. (MM)
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PPHMD
DateTimeSourceHeadlineSymbolCompany
30/03/201909:42Business WireAnnouncing VanEck Vectors ETFs’ March 2019 DistributionsNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
27/12/201810:37Business WireAnnouncing VanEck Vectors Equity ETFs December 2018 DistributionNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
18/10/201802:48Business WireVanEck Launches ESPO, ETF Focused on Fast Growing Video Game and eSports IndustryNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
29/09/201808:03Business WireAnnouncing VanEck Vectors Equity ETFs’ September 2018 DistributionsNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
30/06/201808:15Business WireAnnouncing VanEck Vectors Equity ETFs June 2018 DistributionsNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
30/03/201808:58Business WireAnnouncing VanEck Vectors Equity ETFs March 2018 DistributionsNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
11/11/200901:30PR Newswire (US)New Study in Clinical Cancer Research Shows Therapeutic Promise of Peregrine's Bavituximab With Radiation in a Lethal Brain CancNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
05/11/200906:17PR Newswire (US)Peregrine Pharmaceuticals Awarded Second Broad U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting AntibodiesNASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
04/11/200907:00PR Newswire (US)Peregrine Pharmaceuticals Regains Full Compliance With Nasdaq Continued Listing RequirementsNASDAQ:PPHMD
27/10/200923:17Edgar (US Regulatory)Current report filing (8-K)NASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
24/10/200908:34Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
22/10/200900:30PR Newswire (US)Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast CancerNASDAQ:PPHMD
20/10/200900:30PR Newswire (US)Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory AffairsNASDAQ:PPHMD
19/10/200923:30PR Newswire (US)Peregrine Pharmaceuticals 1:5 Reverse Stock Split Takes EffectNASDAQ:PPHMD
19/10/200922:44Edgar (US Regulatory)Current report filing (8-K)NASDAQ:PPHMDPeregrine Pharmaceuticals Inc. (MM)
 Showing the most relevant articles for your search:NASDAQ:PPHMD

Your Recent History

Delayed Upgrade Clock